Certara Reports Q1 Net Loss, Misses EPS, Updates Guidance After Divesting Medical Writing Business

summarizeSummary

Certara reported a Q1 net loss and missed adjusted EPS estimates, leading to a negative financial outlook, despite completing the strategic divestiture of its Medical Writing business for up to $135 million and updating its full-year guidance.

check_boxKey Events

• Q1 Financial Performance Misses Estimates

  Certara reported a net loss of $8.8 million for Q1 2026, a significant decrease from a net income of $4.7 million in Q1 2025. Adjusted EBITDA decreased by 9% to $31.7 million, and adjusted diluted EPS of $0.09 missed the IBES estimate of $0.11.

• Divestiture of Medical Writing Business Completed

  The company completed the sale of its global medical writing and related regulatory services business to Veristat, LLC on May 8, 2026. The transaction includes $85.0 million in cash upfront, $15.0 million in escrow, and up to $35.0 million in contingent earn-out consideration, totaling up to $135 million.

• Updated 2026 Financial Guidance

  Certara updated its full-year 2026 guidance, expecting revenue of $395 million - $405 million (including $18 million from the divested business), with growth excluding the divested business projected at 0% - 4%. Adjusted diluted earnings per share are expected to be in the range of $0.35 - $0.41.

auto_awesomeAnalysis

Certara's first-quarter results show a significant decline in profitability, moving from a net income to a net loss year-over-year and missing adjusted EPS estimates. While the divestiture of its Medical Writing business for up to $135 million is a strategic move to focus on core growth areas and provides a substantial cash infusion, the updated full-year guidance reflects a low growth outlook (0-4% excluding the divested business). This combination of weak financial performance and modest forward guidance, despite a strategic asset sale, indicates ongoing challenges for the company.